These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19437115)

  • 1. Association of interleukin-10 gene variation with breast cancer prognosis.
    Gerger A; Renner W; Langsenlehner T; Hofmann G; Knechtel G; Szkandera J; Samonigg H; Krippl P; Langsenlehner U
    Breast Cancer Res Treat; 2010 Feb; 119(3):701-5. PubMed ID: 19437115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.
    Knechtel G; Hofmann G; Gerger A; Renner W; Langsenlehner T; Szkandera J; Wolf G; Samonigg H; Krippl P; Langsenlehner U
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1813-9. PubMed ID: 20204402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
    Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.
    Snoussi K; Strosberg AD; Bouaouina N; Ben Ahmed S; Chouchane L
    Eur Cytokine Netw; 2005 Dec; 16(4):253-60. PubMed ID: 16464738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
    Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
    Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer.
    Krupa R; Sliwinski T; Morawiec Z; Pawlowska E; Zadrozny M; Blasiak J
    Exp Oncol; 2009 Dec; 31(4):250-1. PubMed ID: 20010525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
    Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
    Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
    Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of cyclin D1 genotype with breast cancer risk and survival.
    Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.
    Choi JY; Lee KM; Park SK; Noh DY; Ahn SH; Chung HW; Han W; Kim JS; Shin SG; Jang IJ; Yoo KY; Hirvonen A; Kang D
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1090-5. PubMed ID: 15894657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
    Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
    Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study.
    Deming SL; Ren Z; Wen W; Shu XO; Cai Q; Gao YT; Zheng W
    Breast Cancer Res Treat; 2007 Sep; 104(3):309-19. PubMed ID: 17063263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.
    Lin C; Chien SY; Kuo SJ; Chen LS; Chen ST; Lai HW; Chang TW; Chen DR
    Jpn J Clin Oncol; 2012 Mar; 42(3):161-7. PubMed ID: 22287721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk.
    Langsenlehner U; Yazdani-Biuki B; Eder T; Renner W; Wascher TC; Paulweber B; Weitzer W; Samonigg H; Krippl P
    Clin Cancer Res; 2006 Feb; 12(4):1392-4. PubMed ID: 16489098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.